Allianz SE Acquires Shares of 13,960 Humana Inc. (NYSE:HUM)

Allianz SE purchased a new stake in Humana Inc. (NYSE:HUM - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 13,960 shares of the insurance provider's stock, valued at approximately $3,549,000.

A number of other hedge funds have also modified their holdings of HUM. FPC Investment Advisory Inc. bought a new position in shares of Humana in the 4th quarter valued at about $27,000. Centricity Wealth Management LLC bought a new position in Humana during the fourth quarter worth about $30,000. LFA Lugano Financial Advisors SA raised its stake in Humana by 56.3% in the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock worth $32,000 after purchasing an additional 45 shares in the last quarter. OFI Invest Asset Management bought a new stake in Humana in the 4th quarter valued at about $33,000. Finally, Atwood & Palmer Inc. grew its position in shares of Humana by 64.5% during the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider's stock worth $39,000 after purchasing an additional 60 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Stock Up 1.9 %

Humana stock traded up $5.00 during midday trading on Thursday, reaching $270.80. The stock had a trading volume of 441,349 shares, compared to its average volume of 1,546,346. The company has a fifty day moving average price of $268.97 and a two-hundred day moving average price of $272.62. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $32.68 billion, a P/E ratio of 27.22, a PEG ratio of 2.05 and a beta of 0.62.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, equities analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.31%. The ex-dividend date of this dividend is Friday, March 28th. Humana's payout ratio is currently 35.58%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on HUM. Piper Sandler increased their price target on Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a research report on Wednesday, January 15th. JPMorgan Chase & Co. decreased their price objective on shares of Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 18th. Cantor Fitzgerald restated a "neutral" rating and set a $290.00 target price on shares of Humana in a research note on Wednesday, February 12th. StockNews.com cut Humana from a "buy" rating to a "hold" rating in a report on Tuesday, March 18th. Finally, Truist Financial lifted their target price on Humana from $260.00 to $290.00 and gave the company a "hold" rating in a research report on Monday, January 6th. Eighteen analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.